Despite promising results in both murine xenograft lymphoma model [57] and small clinical trials using a radiolabeled [131I] MB-1 anti-CD37 antibody [56,58], CD37 initially lost the battle with CD20 for a target used in immunotherapies. This evidence concerns the gene CD37 and lymphoma.